Oncopharmpod
Updates in Oncology Pharmacy: Adjuvant pertuzumab & nilotinib discontinuation (CML)
- Autor: Vários
- Narrador: Vários
- Editor: Podcast
- Duración: 0:20:20
- Mas informaciones
Informações:
Sinopsis
Review of recent FDA action re: oncology pharmacy including review of the APHINITIY trial and pertuzumab's subsequent approval in the adjuvant setting. Also, the nilotinib label change allowing for discontinuation in CML patients is discussed.
